Viltolarsen is a Antisense Oligonucleotide owned by Nippon Shinyaku, and is involved in 9 clinical trials, of which 5 were completed, and 4 are ongoing. Viltolarsen (NS-065) is based on the exon skipping technology which skips exon 53. Exon skipping is a therapeutic approach based on the use of a synthetic oligonucleotide, called an antisense oligonucleotide, to restore the amino acid reading frame by artificially skipping certain exons of the transcription product (mRNA) to be translated into protein. Then Exon 51 can now join up to exon 54 and continue to make the rest of the protein, with exons 52 and 53 missing in the middle. Therefore, exon 53 skipping by NS-065 (NCNP-01) be able to reduce the symptoms of Duchenne muscular dystrophy.
The revenue for Viltolarsen is expected to reach a total of $3.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Viltolarsen NPV Report.
Viltepso is formulated as solution for intravenous route of administration. Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Viltolarsen (NS-065) is under development for the treatment of Duchenne muscular dystrophy (DMD). It acts by targeting Dystrophin.
Nippon Shinyaku Overview
Nippon Shinyaku develops, manufactures, and sells ethical pharmaceuticals and functional foods. The company offers a wide range of products including drugs for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases among others. Nippon Shinyaku also provides functional food ingredients including health food ingredients, preservatives, spices and condiments, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.
The company reported revenues of (Yen) JPY137,484 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 20.6%, compared to an operating margin of 21.4% in FY2021. In FY2022, the company recorded a net margin of 16.8%, compared to a net margin of 17% in FY2021. The company reported revenues of JPY35,517 million for the second quarter ended September 2022, a decrease of 0.3% over the previous quarter.
Quick View – Viltolarsen
|Highest Development Stage|